NewcelX AG, formerly NLS Pharmaceutics AG, is a Switzerland-based company primarily engaged in the biotechnology industry. The Company focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The Company offers products like Quilience, which is a clinical-stage pharmaceutical compound. It aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The Company also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The Company is a publicly traded company, listing on the NASDAQ.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	47.71M 0 15.36M 13.72M 12.68M 11.49M 21.49M 1.46B 21.85M 153M 60.39M 764M 57.66M 56.44M 2.41B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	47.71M 0 15.36M 13.72M 12.68M 11.49M 21.49M 1.46B 21.85M 153M 60.39M 764M 57.66M 56.44M 2.41B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	34.42%	Yield 2026 *	-	Yield 2027 *	-

Sep. 28	Newcelx Ltd. Advances Ind-Enabling Activities for Ncel-101 Following Successful Fda Pre-Ind Meeting	CI
Sep. 18	NewcelX Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
Aug. 09	NewcelX Ltd. announced that it has received $1.399991 million in funding	CI
Jul. 30	NewcelX Ltd. announced that it expects to receive $1.399991 million in funding	CI
Jul. 15	NewcelX Obtains Patent in Brazil for Potential Type 1 Diabetes Treatment	MT
Jul. 08	Newcelx Ltd. Announces Appointment of Camillo Ricordi to Scientific Advisory Board	CI
Jul. 06	NewcelX Ltd. announced that it has received $2.940234 million in funding	CI
Jul. 01	NewcelX Ltd. Announces Successful FDA Pre-IND Meeting With Clear Path Forward For NCEL-101 Toward Starting Clinical Trials For Type 1 Diabetes	CI
Jun. 15	NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential Of Its Stem Cell Technology Platform	CI
May. 27	Newcelx submits pre-IND package to FDA for NCEL-101 for treatment of type 1 diabetes	RE
May. 27	NewcelX Submits Pre-IND Package To FDA For NCEL-101 For The Treatment Of Type 1 Diabetes	CI
Apr. 30	NewcelX Ltd. announced that it has received $1.349994 million in funding	CI
Apr. 29	NewcelX Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Sep. 28	NewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a Cure for Type 1 Diabetes	AQ
Jul. 31	NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing	AQ
Jul. 15	NewcelX Granted Patent in Brazil for NCEL-101 in Type 1 Diabetes, Expanding Global IP Portfolio	AQ
Jul. 08	NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board	AQ
Jul. 08	The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
KADIMASTEM	-.--%	-8.93%	-	-	15.36M
WUXI APPTEC CO., LTD.	+2.41%	+0.29%	+42.02%	+71.57%	64.69B
ARGENX SE	-0.15%	+7.50%	+11.01%	+73.48%	54.78B
LONZA GROUP AG	+0.57%	+4.60%	+10.07%	+92.86%	53.49B
IQVIA HOLDINGS INC.	+0.37%	+4.67%	+27.03%	+52.07%	45.98B
BEONE MEDICINES AG	-1.21%	+2.32%	+21.80%	+123.81%	42.94B
REVOLUTION MEDICINES, INC.	-0.37%	+5.07%	+249.91%	+918.74%	40.08B
CELLTRION, INC.	+0.05%	+0.21%	+18.26%	+58.53%	33.52B
GENMAB A/S	-0.38%	+5.68%	+36.43%	+27.54%	23.67B
WUXI BIOLOGICS (CAYMAN) INC.	+1.19%	-4.98%	+29.01%	-0.65%	23.97B
Average	+0.25%	+2.41%	+49.51%	+157.55%	42.57B
Weighted average by Cap.	+0.39%	+2.73%	+47.57%	+158.58%

	2026 *	2027 *
Net sales	-	-
Net income	-	-
Net Debt	-	-

Kadimastem Stock TEL AVIV STOCK EXCHANGE

Stocks

KDST

IL0011284614

Biotechnology & Medical Research

Valuation: Kadimastem

Chart: Kadimastem

Latest news: Kadimastem

Analysts' recommendations: Kadimastem

Press Releases: Kadimastem

Other Biotechnology & Medical Research

Financials

Company Profile